Poll: Statin use will grow modestly

Share this article:
Poll: statin use will grow modestly
Poll: statin use will grow modestly

A quick poll of 150 US cardiologists and primary care physicians, along with 100 cardiologists in Europe, shows that the new cholesterol guidelines are not going to cause a massive shift in prescribing habits, reports research firm Symphony Health Solutions.

One reason: US doctors said they were already prescribing statins for patients that fall under the new guidelines' “statin benefit groups.” Symphony noted that the new-to-statin patient population group will probably increase statin sales by around 5% in the next year “in stark contrast to ‘the doubling of statin use' that has been discussed.”

Symphony's researchers also expect atorvastatin and Crestor will be major guideline beneficiaries, but that PCSK9s could grow if benefits of the nascent class are even incrementally better than treatments like atorvastatin.

As for the calculator that some say overcalculates the number of patients who could benefit from statins, Symphony's results indicate that most of the polled physicians do not use the 10-year risk score for the majority of patients it is expected to help. Instead, doctors told Symphony that they rely on “clinical judgment and lab tests.” Two-thirds of doctors also told Symphony that they have no intention of ditching lipid ranges, and will continue to use the metric in their practices.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...